BioWorld Asia

March 28, 2007

Algeta Grosses $41M In IPO To Advance Alpharadin Trials

Algeta ASA's IPO on the Oslo Stock Exchange hit the upper end of its target, raising gross proceeds of slightly less than NOK250 million (US$41.1 million). (BioWorld International) Read More

VASTox On Buying Spree; Next Item: A New Identity

Gene Related to Biological Clock Also Has Role in DNA Repair

TiGenix Stocks Gobbled Up As Belgian Biotechs Soar

Clinuvel Adds New Indication For Tanner Turned Compound

EU OKs Three GM Products But Withdraws Five Others

Other News To Note

ProFibrix Raises $11M For User-Friendly Fibrinogen

Today's news in brief

BioWorld

BioWorld briefs for Dec. 31, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 2, 2026.

AND-017 increases RBC and hemoglobin in sickle cell disease

BioWorld Science

Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...

Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact

BioWorld

Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...

Big pharma taps fast Asia innovation in search of next Keytruda

BioWorld

Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...